Discontinued — last reported Q3 '25
Royalty Pharma Gross loans increased by 1.5% to $17.32B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.0%, from $15.75B to $17.32B. Over 5 years (FY 2020 to FY 2025), Gross loans shows an upward trend with a 5.7% CAGR.
Growth indicates an expansion of lending activities, while a decline may signal tighter credit standards or reduced demand.
This represents the total principal amount of all loans issued by the company before accounting for any reserves or allo...
Common in financial institutions; peers vary based on their risk appetite and focus on commercial versus consumer lending.
bank_gross_loans| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.53B | $14.59B | $14.33B | $14.04B | $14.06B | $14.96B | $14.18B | $14.27B | $14.00B | $13.97B | $14.83B | $14.13B | $14.64B | $15.73B | $15.91B | $15.75B | $15.98B | $16.62B | $17.06B | $17.32B |
| QoQ Change | — | +7.9% | -1.8% | -2.1% | +0.2% | +6.4% | -5.2% | +0.6% | -1.9% | -0.2% | +6.1% | -4.7% | +3.6% | +7.5% | +1.1% | -1.0% | +1.5% | +4.0% | +2.6% | +1.5% |
| YoY Change | — | — | — | — | +3.9% | +2.5% | -1.0% | +1.7% | -0.5% | -6.6% | +4.5% | -1.0% | +4.6% | +12.6% | +7.3% | +11.5% | +9.1% | +5.7% | +7.2% | +10.0% |